Alpern JD et al., 2014-11-13: An NEJM perspective arguing that some off-patent generics became very expensive through shortages, supply disruption and industry consolidation, and that manufacturers holding a legal market monopoly can raise prices unilaterally.
Some older generic drugs have become very expensive, owing to factors including drug shortages, supply disruptions, and consolidations in the generic-drug industry. But generics manufacturers that legally obtain a market monopoly can also unilaterally raise prices.
p. 1859 (abstract)
Alpern JD et al., 2014-11-13: An NEJM perspective arguing that some off-patent generics became very expensive through shortages, supply disruption and industry consolidation, and that manufacturers holding a legal market monopoly can raise prices unilaterally. Perspective/commentary, not a study: no subjects, no comparator, no dose. Country: United States. Funder/conflicts: not stated in the PubMed record; Kesselheim's programme (PORTAL) is Harvard/Brigham based and he has written widely on generic pricing and drug-policy litigation. The abstract quoted does NOT name albendazole or mebendazole – the anthelmintic examples come in the full text, which is paywalled and was not read; hence PARTLY SUPPORTS and MEDIUM. Two 2015 NEJM letters respond to it (PMIDs 25671269, 25671270). The mebendazole-specific price evidence in this run comes from MBA-20, MBA-21 and MBA-22. Study type: other.
